BG103249A - Използване на сибутраминови аналози за понижаваненивата на липидите - Google Patents

Използване на сибутраминови аналози за понижаваненивата на липидите

Info

Publication number
BG103249A
BG103249A BG103249A BG10324999A BG103249A BG 103249 A BG103249 A BG 103249A BG 103249 A BG103249 A BG 103249A BG 10324999 A BG10324999 A BG 10324999A BG 103249 A BG103249 A BG 103249A
Authority
BG
Bulgaria
Prior art keywords
sibutramine
lipid
rods
analysis
compound
Prior art date
Application number
BG103249A
Other languages
English (en)
Other versions
BG64472B1 (bg
Inventor
Finian Kelly
Paul Jones
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG103249A publication Critical patent/BG103249A/bg
Publication of BG64472B1 publication Critical patent/BG64472B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Analogue/Digital Conversion (AREA)

Abstract

Изобретението се отнася до съединение с формула, посочена в описанието, в която R1 и R2, независимоедин от друг, са Н или метил, например N,N-диметил-1-[1-(4-хлорофенил)циклобутил]-3-метилбутил аминхидрохлорид, незадължително във формата на неговиямонохидрат. Съединението или неговите фармацевтично приемливи соли се използват за понижаване нивата на липидите и/или повишаване на HDL:LDL холестеролното съотношение, например при хора с хиперлипидемия, хиперхолестеролемия или хиперглицеридемия.
BG103249A 1996-09-25 1999-03-15 Използване на сибутраминови аналози за понижаване нивата на липидите BG64472B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619961.7A GB9619961D0 (en) 1996-09-25 1996-09-25 Medical treatment

Publications (2)

Publication Number Publication Date
BG103249A true BG103249A (bg) 1999-09-30
BG64472B1 BG64472B1 (bg) 2005-04-30

Family

ID=10800447

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103249A BG64472B1 (bg) 1996-09-25 1999-03-15 Използване на сибутраминови аналози за понижаване нивата на липидите

Country Status (26)

Country Link
US (1) US6187820B1 (bg)
EP (1) EP0973511B1 (bg)
JP (1) JP4143126B2 (bg)
KR (1) KR100573333B1 (bg)
CN (1) CN1173696C (bg)
AT (1) ATE239459T1 (bg)
AU (1) AU724645B2 (bg)
BG (1) BG64472B1 (bg)
BR (1) BR9711411A (bg)
CA (1) CA2266378C (bg)
CZ (1) CZ291879B6 (bg)
DE (1) DE69721833T2 (bg)
DK (1) DK0973511T3 (bg)
ES (1) ES2199354T3 (bg)
GB (1) GB9619961D0 (bg)
HU (1) HU224711B1 (bg)
IL (1) IL128820A (bg)
NO (1) NO991424D0 (bg)
NZ (1) NZ334550A (bg)
PL (1) PL190017B1 (bg)
PT (1) PT973511E (bg)
RU (1) RU2197959C2 (bg)
SK (1) SK284282B6 (bg)
TR (1) TR199900648T2 (bg)
UA (1) UA63916C2 (bg)
WO (1) WO1998013034A1 (bg)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
AU3894500A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
HRP20050307A2 (en) * 2002-10-05 2006-12-31 Hanmi Pharm. Co. Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
WO2004096202A1 (en) * 2003-04-28 2004-11-11 Cipla Limited Pharmaceutical formulation comprising anti-obesity agent and acidulant
US20050032908A1 (en) * 2003-08-04 2005-02-10 Beckman Kristen M. Methods for treating metabolic syndrome
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
KR100618176B1 (ko) 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
US7432398B2 (en) 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
EP2066329B1 (en) 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cyclobutylmethylamines
AU2007322477A1 (en) * 2006-11-22 2008-05-29 Sk Chemicals Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
WO2010082216A2 (en) * 2008-12-08 2010-07-22 Matrix Laboratories Ltd Novel salts of sibutramine and their crystal forms
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2797870B1 (en) 2011-12-30 2019-02-20 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using 1-[1-phenyl-cyclobutyl]isobutylamine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
SK32099A3 (en) 1999-12-10
UA63916C2 (uk) 2004-02-16
NO991424L (no) 1999-03-24
EP0973511B1 (en) 2003-05-07
DK0973511T3 (da) 2003-08-25
CN1173696C (zh) 2004-11-03
BR9711411A (pt) 1999-08-17
CN1231605A (zh) 1999-10-13
PL332367A1 (en) 1999-09-13
DE69721833D1 (de) 2003-06-12
HUP9903823A3 (en) 2000-07-28
TR199900648T2 (xx) 1999-06-21
CZ291879B6 (cs) 2003-06-18
CA2266378C (en) 2007-02-13
US6187820B1 (en) 2001-02-13
IL128820A0 (en) 2000-01-31
CZ93299A3 (cs) 2000-07-12
BG64472B1 (bg) 2005-04-30
GB9619961D0 (en) 1996-11-13
NZ334550A (en) 2000-09-29
NO991424D0 (no) 1999-03-24
ES2199354T3 (es) 2004-02-16
WO1998013034A1 (en) 1998-04-02
PT973511E (pt) 2003-08-29
AU4774197A (en) 1998-04-17
IL128820A (en) 2001-10-31
JP2001500883A (ja) 2001-01-23
JP4143126B2 (ja) 2008-09-03
KR100573333B1 (ko) 2006-04-24
KR20000048567A (ko) 2000-07-25
HUP9903823A2 (hu) 2000-06-28
SK284282B6 (sk) 2004-12-01
PL190017B1 (pl) 2005-10-31
HU224711B1 (en) 2006-01-30
EP0973511A1 (en) 2000-01-26
ATE239459T1 (de) 2003-05-15
AU724645B2 (en) 2000-09-28
CA2266378A1 (en) 1998-04-02
DE69721833T2 (de) 2003-12-24
RU2197959C2 (ru) 2003-02-10

Similar Documents

Publication Publication Date Title
DK0973511T3 (da) Anvendelse af sibutraminanaloger til at sænke lipidniveauer
DK0814788T3 (da) Forbedring af glucosetolerance
ATE232720T1 (de) Adjuvans für impfstoff
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
BG103277A (bg) Използване на сибутраминови аналози за предотвратяване развитието на диабет
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
PT788481E (pt) Processo para preparacao de levobupivacaina e seus analogos
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
IL101327A0 (en) Heterocyclic-cyclic amine derivatives
BR9806568A (pt) Forma de cristal de n-(4-trifluormetilfenil)-5-metilisoxazol-4-carboxamida
KR960007592A (ko) 신규한 피롤로카바졸
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
BR0214742A (pt) Polimorfo cristalino de cloridrato de venlafaxina e métodos para sua preparação
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
NO20002588L (no) Bifenylamidinderivater
UA37217C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
ATE282608T1 (de) Chinoxalindionen
EA199900688A1 (ru) Хиноксалиндионы
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica
ATE170365T1 (de) Fungizide mischungen
BR9503776A (pt) Processo para a preparação de (-)-n-metil-n-(4(4-fenil-4-acetil-amino-piperidin-1-il)-2-(3-,4-dicloro-fenil)-butil)-benzamida e seus sais farmaceuticamente aceitáveis
BR9814377A (pt) Processo para preparação de isopropil-metil-[2-(3-propoxifenóxi) etil]amina, composto, e, formulação farmacêutica
RU93046412A (ru) N-ПРОИЗВОДНЫЕ (ФЕНИЛЭТИЛ- β -ОЛ)АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ